SEC Form 4 · accession 0001384101-19-000024
VERACYTE, INC. · VCYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Giulia C Kennedy
Officer — Chief Scientific & Med Officer
Period of report
Feb 28, 2019
Accepted (ET)
Mar 4, 2019 · 7:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001384101
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 28, 2019 | A | 8,000 | $0.00 | A | 17,400 | D | |
| Common StockF2 | Feb 28, 2019 | A | 32,000 | $0.00 | A | 49,400 | D | |
| Common Stock | Feb 28, 2019 | M | 397 | $10.45 | A | 49,797 | D | |
| Common Stock | Feb 28, 2019 | M | 11,667 | $8.86 | A | 61,464 | D | |
| Common Stock | Feb 28, 2019 | M | 8,749 | $6.45 | A | 70,213 | D | |
| Common Stock | Feb 28, 2019 | M | 4,166 | $5.43 | A | 74,379 | D | |
| Common Stock | Feb 28, 2019 | M | 12,396 | $9.05 | A | 86,775 | D | |
| Common StockF3 | Feb 28, 2019 | S | 36,075 | $20.4168 | D | 50,700 | D | |
| Common StockF4 | Feb 28, 2019 | S | 1,300 | $21.2833 | D | 49,400 | D | |
| Common StockF5 | Feb 28, 2019 | F | 813 | $0.00 | D | 48,587 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F6 | $20.21 | Feb 28, 2019 | A | 60,000 | A | — | Feb 27, 2029 | Common Stock | 60,000 | 60,000 | D |
| Stock Option (right to buy)F7 | $10.45 | Feb 28, 2019 | M | 397 | D | — | Sep 15, 2024 | Common Stock | 397 | 12,885 | D |
| Stock Option (right to buy)F8 | $8.86 | Feb 28, 2019 | M | 11,667 | D | — | Mar 1, 2025 | Common Stock | 11,667 | 1,667 | D |
| Stock Option (right to buy)F9 | $6.45 | Feb 28, 2019 | M | 8,749 | D | — | Feb 28, 2026 | Common Stock | 8,749 | 16,253 | D |
| Stock Option (right to buy)F10 | $5.43 | Feb 28, 2019 | M | 4,166 | D | — | Mar 14, 2026 | Common Stock | 4,166 | 6,773 | D |
| Stock Option (right to buy)F11 | $9.05 | Feb 28, 2019 | M | 12,396 | D | — | Mar 2, 2027 | Common Stock | 12,396 | 44,271 | D |
Explanation of responses
- F1Restricted stock units awarded on February 28, 2019 vest 25% on March 2, 2020 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.
- F10The option becomes exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
- F11The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
- F2Restricted stock units awarded on February 28, 2019 vest 25% on February 28, 2021 and 75% on February 28, 2022 subject to continuing employment of the Reporting Person on each vesting date.
- F3Represents weighted average sales price. Sale prices for the transactions range from $20.11 to $21.10. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
- F4Represents weighted average sales price. Sale prices for the transactions range from $21.14 to $21.39. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
- F5The reporting person is reporting the withholding of 813 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,350 Restricted Stock Units granted on March 2, 2018. The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4.
- F6The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
- F7The option is fully vested and fully exercisable.
- F8The option becomes exercisable as to 25% of the shares on March 2, 2016, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
- F9The option becomes exercisable as to 25% of the shares on March 1, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.